Alzheimers Association Gets $100K to Expand Support
The grant will build on programs that Alzheimers Association, MA/NH Chapter launched last year in connection with a similar grant from the foundation.
The CVS Health Foundation grant allowed us to expand our efforts to educate clinicians while connecting families with the important care and support programs the Alzheimers Association offers for those confronting an Alzheimers or other dementia diagnosis, said Liz McCarthy, director of professional health care services for the MA/NH Chapter. This new round of funding will help us continue to expand these efforts and reach more individuals and families in need.
The MA/NH Chapter used its first grant round to continue expansion of its Dementia Care Coordination (DCC) program. Through the DCC program, the chapter partners with health care providers or insurers to provide critical ongoing support for diagnosed individuals and their caregivers. The chapter currently partners with 13 organizations through the program.
Since the initial grant, the chapter reported a 22% increase in referrals to the Alzheimers Association. Last year, the Chapter served nearly 1,200 families with DCC.
The chapter said it also was able to expand outreach to primary care physicians with the goal of providing education and a greater opportunity for clinicians to share best practices and provide more accurate and earlier diagnoses.
"The CVS Health Foundation is proud to support the Massachusetts/New Hampshire Chapter in its effort to ensure that patients and caregivers receive the resources they need following an Alzheimers diagnosis and are able to maintain a high-quality of life, said Eileen Howard Boone, president of the foundation. "Weve seen significant results following the first year of the program and look forward to working with the Alzheimers Association to continue to fulfill our programs mission.
There are currently 5.4 million Americans living with Alzheimers disease. Experts say that number will skyrocket to nearly 14 million by 2050 unless effective treatments are found.